RxDoctor Payments Data

Samer Tabbal, MD

Neurology · Miami, FLNPI 1053337279

Payments from drug & device makers

$953in general payments, 2019–2025

Across 16 payments — averaging $59.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$253
  • Boston Scientific$178
  • Abbott$138
  • AbbVie$134
  • Revance Therapeutics, Inc.$88
  • Amneal Pharmaceuticals LLC$86
  • plus $75 from 3 others

What the payments were for

  • Food & beverage$953100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$953 in reported general payments places this provider in the 35th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$34,327
Medicare patients
228
Services billed
290

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine37$419,974
IngrezzaValbenazine Tosylate34$395,301
NuplazidPimavanserin Tartrate41$238,084
RytaryCarbidopa/Levodopa91$109,441
Carbidopa-LevodopaCarbidopa/Levodopa647$33,558
Droxidopa24$28,913
Rasagiline Mesylate152$23,848
Entacapone99$22,249
Carbidopa25$15,777
OngentysOpicapone16$13,210
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone52$12,145
AmantadineAmantadine Hcl131$10,074
Rivastigmine16$3,590
Donepezil Hcl98$3,413
Galantamine ErGalantamine Hbr16$2,721

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza, Ongentys$28$408,51050 claims
Acadia Pharmaceuticals IncNuplazid$17$238,08441 claims
Amneal Pharmaceuticals LLCRytary$86$109,44191 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,434 neurology providers in Florida.

Other neurology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →